File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Cetuximab beyond progression in Kras wild-type metastatic colorectal cancer

TitleCetuximab beyond progression in Kras wild-type metastatic colorectal cancer
Authors
Lam, KOLee, VChoi, CWSze, HCKKwok, RCCShum, BCYWong, IWCTsang, JWHLiu, RKYLeung, TWKwong, DLW
KeywordsMedical sciences
Oncology
Issue Date2013
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The ESMO 15th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 3-6 July 2013. In Annals of Oncology, 2013, v. 24 suppl. 4, p. iv108, abstract P-0254 How to Cite?
DOI: http://dx.doi.org/10.1093/annonc/mdt203.252
AbstractBACKGROUND: Cetuximab and bevacizumab have proven efficacy in the treatment of metastatic colorectal cancer (mCRC). Although new agents such as panitumumab, aflibercept and regorafenib emerge with modest clinical benefit, they are still not widely available. With limited options of target therapy, treatment with individual agent beyond progression is an attractive strategy and use of bevacizumab in this setting has been shown to improve survival. However, evidence for applying the same strategy to cetuximab is not clear. We performed a retrospective analysis to evaluate the clinical benefit of cetuximab beyond progression in Kras wild-typ…
DescriptionPosters: P-0254
Persistent Identifierhttp://hdl.handle.net/10722/186710
ISSN
0923-7534
2019 Impact Factor: 18.274
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorLam, KOen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorChoi, CWen_US
dc.contributor.authorSze, HCKen_US
dc.contributor.authorKwok, RCCen_US
dc.contributor.authorShum, BCYen_US
dc.contributor.authorWong, IWCen_US
dc.contributor.authorTsang, JWHen_US
dc.contributor.authorLiu, RKYen_US
dc.contributor.authorLeung, TWen_US
dc.contributor.authorKwong, DLWen_US
dc.date.accessioned2013-08-20T12:18:05Z-
dc.date.available2013-08-20T12:18:05Z-
dc.date.issued2013en_US
dc.identifier.citationThe ESMO 15th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 3-6 July 2013. In Annals of Oncology, 2013, v. 24 suppl. 4, p. iv108, abstract P-0254en_US
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/186710-
dc.descriptionPosters: P-0254-
dc.description.abstractBACKGROUND: Cetuximab and bevacizumab have proven efficacy in the treatment of metastatic colorectal cancer (mCRC). Although new agents such as panitumumab, aflibercept and regorafenib emerge with modest clinical benefit, they are still not widely available. With limited options of target therapy, treatment with individual agent beyond progression is an attractive strategy and use of bevacizumab in this setting has been shown to improve survival. However, evidence for applying the same strategy to cetuximab is not clear. We performed a retrospective analysis to evaluate the clinical benefit of cetuximab beyond progression in Kras wild-typ…-
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleCetuximab beyond progression in Kras wild-type metastatic colorectal canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.emailLee, V: vhflee@hku.hken_US
dc.identifier.emailChoi, CW: hcchoi@hku.hken_US
dc.identifier.emailSze, HCK: henrysze@graduate.hku.hken_US
dc.identifier.emailTsang, JWH: jwhtsang@hku.hken_US
dc.identifier.emailLiu, RKY: ricoliu@hkucc.hku.hken_US
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hken_US
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.authorityLee, V=rp00264en_US
dc.identifier.authoritySze, HCK=rp01697en_US
dc.identifier.authorityTsang, JWH=rp00278en_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/annonc/mdt203.252-
dc.identifier.hkuros218675en_US
dc.identifier.volume24en_US
dc.identifier.issuesuppl. 4-
dc.identifier.spageiv108, abstract P-0254-
dc.identifier.epageiv108, abstract P-0254-
dc.publisher.placeUnited Kingdom-
dc.customcontrol.immutablesml 140409-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats